A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds

Title:A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds

Volume: 31 Issue: 30

Author(s): Hua Zhang, Wen Zhang*, Mengyu Zhu and Annoor Awadasseid

Affiliation:

• Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, China
• Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou, 310014, China

Abstract: Cancers are a huge threat to human life and health. Every year, many people suffer and die from various cancers, and numerous resources have been used to combat cancer. Due to several disadvantages of anticancer agents, such as drug-induced side effects, drug resistance, etc., there are still wide gaps in their ability to conquer cancer. Therefore, there is an urgent need to discover and develop many novel chemotypes to suppress cancer. In this review, we mainly focus on the anticancer potency of two representative sorts of carbazole-based compounds: carboline derivatives and diazacarbazole derivatives. Diazacarbazole derivatives, which have not been fully explored yet, might bring us a new vision and a valuable opportunity for overcoming the enormous hurdle we are now facing in the cancer campaign. We also provide several synthetic approaches for constructing the critical skeletons of the carbazole-based tricyclic compounds.

Cite this article as:

Zhang Hua, Zhang Wen*, Zhu Mengyu and Awadasseid Annoor, A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds, Current Medicinal Chemistry 2024; 31 (30) . https://dx.doi.org/10.2174/0929867331666230825104254